Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20

Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20–243 CrossMab

Published:2014-03-26 Issue:3 Volume:6 Page:739-747
ISSN:1942-0870
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Zhao Lei,Xie Feiyue,Tong Xin,Li Huafei,Chen Yaling,Qian Weizhu,Duan Shuyan,Zheng Juan,Zhao Ziye,Li Bohua,Zhang Dapeng,Zhao Jian,Dai Jianxin,Tong Xin,Hou Sheng,Guo Yajun

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.28613

Reference45 articles.

1. Non-Hodgkin lymphoma

2. Non-Hodgkin lymphoma: an update

3. Mechanisms of killing by anti-CD20 monoclonal antibodies

4. Evolution of anti- CD20 monoclonal antibody therapeutics in oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific Antibodies for IFN-β Delivery to ErbB2+ Tumors;Biomolecules;2021-12-20

2. Streamlined Human Cell-Based Recombinase-Mediated Cassette Exchange Platform Enables Multigene Expression for the Production of Therapeutic Proteins;ACS Synthetic Biology;2021-06-16

3. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity;Journal of Nanobiotechnology;2021-01-09

4. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins;mAbs;2021-01-01

5. Design and Production of Bispecific Antibodies;Antibodies;2019-08-02